Smith & Nephew plc (SN) Given Consensus Rating of “Hold” by Brokerages

Smith & Nephew plc (LON:SN) has earned an average recommendation of “Hold” from the eleven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is GBX 1,317.30 ($17.86).

SN has been the topic of a number of recent analyst reports. Citigroup reiterated a “sell” rating and set a GBX 1,160 ($15.73) price target on shares of Smith & Nephew in a research report on Friday, October 6th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,361 ($18.46) price target on shares of Smith & Nephew in a research report on Tuesday, October 10th. Jefferies Group reiterated a “buy” rating and set a GBX 1,515 ($20.55) price target on shares of Smith & Nephew in a research report on Thursday, October 12th. Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew in a research report on Friday, October 13th. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 1,340 ($18.17) price target on shares of Smith & Nephew in a research report on Friday, November 3rd.

Shares of Smith & Nephew (SN) opened at GBX 1,255.50 ($17.03) on Friday. The company has a market capitalization of $11,020.00 and a PE ratio of 1,743.75. Smith & Nephew has a 1-year low of GBX 1,143 ($15.50) and a 1-year high of GBX 1,442 ($19.56).

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/12/smith-nephew-plc-sn-given-consensus-rating-of-hold-by-brokerages.html.

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply